[Correspondence] Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation

SARS-CoV-2 continues to evolve, with successive variants evading immunity established by previous infection or vaccination. In mid-2024, a vaccine tailored to the JN.1 variant was authorised by the European Medicines Agency (EMA), which boosted neutralising antibody responses and provided substantial protection against severe disease and hospitalisation.1–3 Around 6 months later, in January 2025, LP.8.1 (of the JN.1 lineage) was classified as a “variant under monitoring” by WHO, due to its epidemiological importance and enhanced transmission fitness relative to contemporaneous strains.